

CDW HOLDING LIMITED
(Incorporated in Bermuda)
(Company Registration No. 35127)

INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT AGREEMENT

The Board of Directors (the “**Board**”) of CDW Holding Limited (the “**Company**”) is pleased to announce that it has on 23 August 2016, entered into an Intellectual Property Rights (“**IPR**”) Assignment Agreement (the “**Agreement**”) with Meisterbio Co., Limited (“**Meisterbio**”).

Pursuant to the terms of the Agreement, Meisterbio will transfer current (and future) IPR and facilities relating to its research to the Company for a consideration sum of 100,000,000 JPY (approximately S\$1.35 million) which was paid in cash and arrived at on a willing-buyer and willing-seller basis having taken into consideration ongoing and future research expenses and the contributions of the research to the Company. The Company and Meisterbio have both agreed that Meisterbio would be the nominee applicant for any patent registrations related to the research.

Under the terms of the Agreement, once the patents are granted, the Company will be assigned the IPR to the following:

1. Amphiphilic composition containing resveratrol, and production method thereof
2. Composition for internal use, containing pterostilbene glycoside
3. Composition for external use, containing pterostilbene glycoside
4. Glycosylation method stilbenoid compound
5. Composition for external use, containing pinostilbene and glycoside thereof
6. Composition for internal use, containing pinostilbene and glycoside thereof
7. Type17 Collagen production-promoting agent
8. Fourth place pinosuchiruben selective glycosidate method using a glycosyltransferase

As the owner of the IPR, the Company will have exclusive manufacturing and selling rights to any products developed from the research.

Information on Meisterbio

Established in 2008, Meisterbio is a Japanese corporation involved in research and development as well as the sale of bioactive compounds for health food and cosmetic applications.

None of the directors, controlling shareholder or any of their respective associates has any interest, direct or indirect, in the above-mentioned acquisition save through their shareholding (if any) in the Company.

BY ORDER OF THE BOARD

Dy Mo Hua Cheung, Philip
Executive Director
24 August 2016